Drugs / Creatine
Creatine
Trials 37
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02463305 | Aug 2022 → Mar 2023 | ulcerative colitis | University of Colorado, Denver | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 11 trial | ||||||
| Phase 1 | NCT02058654 | Dec 2013 → Jun 2014 | nutritional disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07666815 | Mar → Jul 2026 overdue | end stage renal failure | Pedro Julian Flores Moreno | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00026988 | Oct 2001 → Jun 2006 | Huntington disease | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 214 trials · 1 missed | ||||||
| Phase 2 | NCT06967428 | Sep 2025 → Jan 2026 overdue | — | Independent Medical Alliance | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05895747 | Sep 2023 → Jun 2026 overdue | major depressive disorder | University of Utah | Recruiting | No outcome recorded |
| Phase 2 | NCT04471792 | May 2020 → Dec 2022 | peripheral arterial disease | Florida State University | Completed | Missed primary |
| Phase 2 | NCT03530202 | Jan → Jul 2018 | muscular atrophy | University of Regina | Unknown | No outcome recorded |
| Phase 2 | NCT01543139 | Dec 2015 → Apr 2017 | bipolar depression | Ewha Womans University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01257581 | Mar 2011 → Dec 2012 | amyotrophic lateral sclerosis | Nazem Atassi | Completed | No outcome recorded |
| Phase 2 | NCT01411163 | Apr 2010 → May 2013 | Huntington disease | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01411150 | May 2009 → Sep 2012 | Huntington disease | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00851006 | Apr 2009 → Dec 2012 | major depressive disorder | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT01412151 | Apr 2005 → Nov 2011 | Huntington disease | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00063193 | May 2003 → May 2005 | Parkinson disease | University of Rochester | Completed | No outcome recorded |
| Phase 2 | NCT00070993 | Dec 2002 → May 2006 | amyotrophic lateral sclerosis | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2 | NCT00005674 | — | amyotrophic lateral sclerosis | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2 | NCT00005766 | — | amyotrophic lateral sclerosis | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00016653 | Jun 2000 → Dec 2006 | Duchenne muscular dystrophy | Cooperative International Neuromuscular Research Group | Completed | Missed primary |
| Phase 36 trials · 1 missed | ||||||
| Phase 3 | NCT04504253 | Aug 2020 → Aug 2023 | major depressive disorder | University of Utah | Completed | No outcome recorded |
| Phase 3 | NCT02568878 | Nov 2015 → Oct 2016 overdue | anxiety, depressive disorder, methamphetamine dependence | Montana State University | Recruiting | No outcome recorded |
| Phase 3 | NCT02188849 | Oct 2014 → Jul 2015 | myopathy | University of Chile | Completed | No outcome recorded |
| Phase 3 | NCT00140192 | Sep 2004 → Mar 2006 | schizophrenia | Beersheva Mental Health Center | Completed | Missed primary |
| Phase 3 | NCT00069186 | Jun 2003 → Apr 2005 | amyotrophic lateral sclerosis | The Avicena Group | Unknown | No outcome recorded |
| Phase 3 | NCT00018109 | — | Duchenne muscular dystrophy | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT06991426 | Jul → Sep 2025 overdue | chronic obstructive pulmonary disease | Federal University of São Paulo | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03433651 | Jan 2019 | depressive disorder | Mike O'Callaghan Military Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT03202095 | Aug 2017 → Jun 2024 | major depressive disorder | University of Utah | Withdrawn | No outcome recorded |
| Phase 4 | NCT02356107 | Apr 2015 → Aug 2016 | major depressive disorder | Perry Renshaw | Completed | No outcome recorded |
| Phase 4 | NCT01514630 | Jan 2013 → Dec 2014 | depressive disorder, substance abuse | Perry Renshaw | Completed | No outcome recorded |
| Phase 4 | NCT01175616 | Sep 2012 → Apr 2014 | major depressive disorder | University of Utah | Withdrawn | No outcome recorded |
| Phase not applicable6 trials · 1 missed | ||||||
| — | NCT07534293 | Feb 2026 | — | Universitas Negeri Malang | Completed | No outcome recorded |
| — | NCT01502813 | Feb 2012 → Oct 2018 | — | Deborah Yurgelun-Todd | Completed | No outcome recorded |
| — | NCT02189915 | Jan 2012 → Oct 2015 | depressive disorder, substance-related disorder | Perry Renshaw | Terminated | No outcome recorded Stop: Business |
| — | NCT00348933 | Jul 2006 → Feb 2010 | Angelman syndrome | University of California, San Diego | Completed | Missed primary |
| — | NCT00465140 | Jan 2004 → Jan 2007 | impaired renal function disease | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00473902 | Aug 2003 → Sep 2004 | muscular atrophy | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 0 | NCT04073381 Background | Oct 2018 → Jul 2020 | — | University of Texas at Austin | Completed | No outcome recorded |
| Phase 0 | NCT01601210 Comparator | Jun 2012 → May 2014 | major depressive disorder | Perry Renshaw | Completed | No outcome recorded |
| Phase 2 | NCT04395183 Comparator | Mar 2021 → Aug 2023 | major depressive disorder | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00592995 Comparator | Dec 2007 → Sep 2012 | Huntington disease | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00355576 Background | Jul 2006 → May 2007 | amyotrophic lateral sclerosis | Columbia University | Completed | No outcome recorded |
| Phase 3 | NCT07372144 Comparator | Aug 2026 → Jun 2028 expected | breast cancer | D'Or Institute for Research and Education | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT00712426 Comparator | Sep 2009 → Dec 2014 | Huntington disease | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00449865 Comparator | Mar 2007 → Sep 2013 | Parkinson disease | University of Rochester | Terminated | No outcome recorded |
| Phase 4 | NCT02922725 Comparator | Nov 2016 → May 2020 | major depressive disorder | Brent Michael Kious, MD, PhD | Terminated | No outcome recorded |
| Phase 4 | NCT02134808 Comparator | Nov 2014 → Jun 2017 | major depressive disorder | Perry Renshaw | Completed | No outcome recorded |
| Phase 4 | NCT02192931 Comparator | Sep 2014 → Jan 2023 | depressive disorder, drug dependence | Perry Renshaw | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 50 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Creatine | “This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to...” NCT06967428 ↗24“Will receive CreaSafe® creatine (0.03 g/kg/day) for 90 days, orally administered diluted in water, every morning (between 7:00 and 9:00 a.m.)” NCT06991426 ↗ “114 eligible subjects will be randomized to receive treatment for 6 months of (1) active creatine or (2) placebo.” NCT00005766 ↗ |
| Known as | Cosmocair c 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL283800 ↗ |
| Known as | creatine monohydrate | “Participants assigned to this arm will receive oral creatine monohydrate at a dose of 5 g per day, dissolved in water and administered once daily.” NCT07372144 ↗24“The nutrition supplement cocktail will include whey protein, creatine monohydrate, and L-citrulline.” NCT04073381 ↗ “Creatine monohydrate supplementation may enhance cognitive functions in healthy subjects.” PMID 17592912 ↗ Jun 2007 “Dietary Supplement: Creatine monohydrate” NCT04504253 ↗ |
| Known as | CrM | “We examined whether creatine monohydrate (CrM) and conjugated linoleic acid (CLA) could enhance strength gains and improve body composition (i.e., increase fat-free mass (FFM);...” NCT00473902 ↗ |
| Known as | Kreatinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL283800 ↗ |
| Known as | Neotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL283800 ↗ |
| Known as | NSC-8752 | ChEMBL registry synonym — accepted as the source's own label CHEMBL283800 ↗ |
| Action | Inhibit | “it could directly inhibit apoptotic neuronal death through its inhibitory action on the mitochondrial transition pore.” NCT00026988 ↗ |
| Modality | Small molecule | “Creatine is an organic acid occurring naturally in vertebrates” NCT01514630 ↗ |
| Route | Oral | “Boys with DMD who are enrolled in this trial will be randomly chosen to receive creatine monohydrate or glutamine or an inactive placebo orally for six months.” NCT00016653 ↗ |